AzTrials
AzTrials

Absorption; ChemicalsCAROPROTNCT04078646

Influence of Proteins on the Bioavailability of Carotenoids

A study testing Intervention with soy protein isolate, Intervention with whey protein and Intervention without protein addition in people with Absorption; Chemicals and Healthy Diet, run by Luxembourg Institute of Health at 1 site in Luxembourg.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A postprandial intervention study is conducted on healthy male subjects to evaluate whether the addition of proteins (why protein isolate, soy protein) can help to increase the bioavailability of carotenoids from a tomato/carrot beverage. Read more about this study

Who is it for?
Ages 20 to 50 years, men onlyHealthy volunteers can take part
Conditions the study is for
Absorption; Chemicals, Healthy Diet, Metabolism
What is being tested?
Intervention with soy protein isolate, Intervention with whey protein and Intervention without protein addition
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteLuxembourg
Study dates
11 Oct 2019to 30 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • healthy and free living;
  • men;
  • age between 20 and 50 years old;
  • Body-Mass-Index (BMI) <30 kg/m2
  • non-smokers (abstinent for more than 2 years);

Who cannot join

  • suffering from any metabolic disease that may cause digestive disturbances (such as Crohn's disease or colitis);
  • malabsorption disorders;
  • BMI over 30 kg/m2;
  • hyperlipidaemia (triglycerides and total cholesterol over 200 mg/dl)
  • any individuals following a special diet that is not compatible with wash-out periods or test meals (vegetarian, gluten-free or diabetic);
  • regular consumption of more than 5 portions (80-100 g) of fruits and vegetables per day;
Show all 14Show fewer
  • being on medical treatment or consuming any medication for chronic conditions or recent illness (e.g. antibiotics);
  • consuming regularly dietary supplements;
  • abnormally high or low values of plasma circulating carotenoids;
  • tobacco smoking;
  • frequent alcohol consumption (over 2 glasses per day);
  • food allergies or intolerances that are not compatible with test meals (e.g. gluten or milk intolerance);
  • daily practice of intense physical activity of 120 min or more.
  • No special population group such as prisoners, children, the mentally disabled or groups whose ability to give voluntary informed consent may be in question, will be recruited for this study.

Trial locations and contacts

1 site in 1 country.

Luxembourg1 site
  • Luxembourg Institute of Health

    Strassen, 1445

Other trials in Luxembourg

About this study

A postprandial intervention study is conducted on healthy male subjects to evaluate whether the addition of proteins (why protein isolate, soy protein) can help to increase the bioavailability of carotenoids from a tomato/carrot beverage.

Read the detailed description

Participants who agree to sign the Informed Consent Form and are considered eligible for participation will be scheduled for a first and brief screening visit enrolment visit) to collect a spot urine and blood sample (20 ml) that are meant to check the subjects anemic status and analyze the sugar levels as well as plasma lipids such as triglycerides, in order to screen for any abnormal health condition (e.g. onset of diabetes) that they might not be aware of at the date of the information session and that might not make them eligible for this study.

If at this stage they are still considered eligible for the study, participants will commence the 4 week trial phase which includes 3 washout periods, 1 short screening visit and 3 full day (i.e. 10.5 hours) clinical visits. The screening visit, called preliminary visit, will take place at the beginning of the trial phase. A blood sample will be collected to determine the baseline levels of triglycerides and plasma carotenoids at the beginning of the trial, prior to the first washout phase.

The first washout week starts on day 1 after the preliminary visit and will have a duration of 14 days during which the participants will be asked to stay on a low carotenoid diet (i.e. to avoid the intake of colored fruits and vegetables), to reduce the basal levels of blood circulating carotenoids.

During the 1-day appointments at the Clinical and Epidemiological Investigation Centre (CIEC), one of the three test meals will be given to the participants in 6 different orders, making 6 treatment patterns. Assuming that all 24 participants are successfully recruited, we will have 4 randomly allocated participants per pattern.

On clinical visit days, participants will be asked to report at the CIEC's facilities, starting from 7:30 am, and a baseline blood sample (20 ml) will be drawn at 0h time point. A trained nurse will insert a cannula in the forearm of the participant that will be left in place during the whole staying for the commodity of the participant.

Immediately after the baseline blood draw, a test meal composed of a mixture of carrot and tomato juice (350 mL in total), to which 5 mL of peanut oil will be added, 40 g of toasted bread (white wheat, with 10 g margarine plus 20 g cream-cheese) and a glass of water (approx. 300 mL) which may or may not contain 30 g of proteins (either a plant based protein or a dairy-based proteins) will be served. The entire test meal must be eaten within 30 min, under supervision.

Post-prandial blood samples (20 ml each) will be collected at timed intervals (before, 2h, 3h, 4h, 5h. 6h, 8h and 10h after test meal intake). Participants will receive a standardized lunch 4 hours after test meal intake (c.a. 12:00 pm), consisting of a toasted sandwich (white wheat bread, ca 60 g), with ca. 60 g turkey with some margarine to spread on the bread (ca 10 g), a Greek yogurt (140 g) and a small apple. A courtesy meal 10 hours after test meal intake for dinner and at the end of the visit. No other foods or beverages except water (ad libitum) will be allowed during the day (including during breakfast and lunch if desired).

This first clinical appointment will be followed by a 1 week washout period, during which he/she will continue on a low carotenoid diet (3rd week of washout diet). At the end of the 3rd week of washout, the second appointment at the LIH clinical center will take place. The procedure for this day is the same as mentioned above. The second appointment is followed by the 4th and last washout week and at the end the participant will have the 3rd and last appointment at the Luxembourg Institute of Health (LIH) clinical center, which will be identical to the other visits. For all washout periods the participants will be asked to fill a provided food journal, on a daily basis, where they will write down what they have eaten during the day. This will be used to check compliance with the washout period and better interpret personal data.

Stool collection: For a limited number of subjects (n=6), the samples will be collected following intake of all 3 test meals. For this purpose, Containers for collection and plastic clip-bags and bags will be handed to participants. Boxes with cooling elements for stool collection will likewise be given. Also, six fecal color markers will be provided to the participants. For each clinical visit, two fecal marker are needed. Collections will start from the excretion of the first fecal color marker (brilliant blue) which will be taken at the beginning of the fasting period, i.e. the day before each clinical day. The collection will continue to the excretion of the second fecal marker which should be taken on the morning of the day following each clinical visit (before breakfast). Samples will be returned after the clinical test day as soon as the last fecal marker has been excreted (normally resulting in 2-3 day complete fecal samples), and could be collected once in between by staff from the LIH if needed.

Being tested
Intervention with soy protein isolate, Intervention with whey protein, Intervention without protein addition
Keywords
Carotenoids, Postprandial absorption, Area-under-curve, Bioavailability, Proteins, Tomato juice, Carrot juice, Randomized cross-over

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intervention with soy protein isolateOther

    Test meals will be served to the subjects, containing soy protein isolate:

    350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil

    as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.

  • Intervention with whey proteinOther

    Test meals will be served to the subjects, containing soy protein isolate:

    350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil

    as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.

  • Intervention without protein additionOther

    Test meals will be served to the subjects, containing soy protein isolate:

    350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil

    as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.

Study groups in NCT04078646
Study groupRoleWhat they receive
Dietary interventionExperimentalIntervention with test meal only
Receives: Other: Intervention without protein addition
Dietary intervention 2ExperimentalIntervention with test meal and whey protein isolate (30 g)
Receives: Other: Intervention with whey protein
Dietary intervention 3ExperimentalIntervention with test meal and soy protein (30 g)
Receives: Other: Intervention with soy protein isolate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concentration of carotenoids in plasma triacyl-rich-lipoprotein (TRL) fraction

    Carotenoid concentration (lycopene, beta-carotene) studied over 10 hours postprandial (area-under curve of concentration vs. time)

    Measured: 10 hours postprandial, measured on 3 test clinical test days after test meal intake, interspersed by 1 week each

Secondary outcomes (3)
  1. Time of maximum concentration of lycopene and beta-carotene and triglycerides in plasma-TRL fraction

    Studying the timely appearance of carotenoids in the plasma TRL fraction, i.e. the time when concentration with reach a maximum

    Measured: 10 hours postprandial, measured on 3 clinical test days after test meal intake, interspersed by 1 week

  2. Maximum concentration of lycopene and beta-carotene and triglycerides in plasma-TRL fraction

    Studying the maximum concentration of lycopene and beta-carotene in the plasma-TRL fraction, i.e. the maximum concentration reached during the 10 h monitoring

    Measured: 10 hours postprandial, measured on 3 test clinical days after test meal intake, interspersed by 1 week

  3. Fecal degradation products of carotenoids

    Studying native carotenoids and degradation products in pooled stool excreted following test meal intake (fecal balance method), i.e. the stool collected following test meal intake

    Measured: Collection covering the test meal intake period, starting from the excretion of a brilliant blue capsule taken the 12 hours before test meal intake, until complete excretion of a second brilliant blue capsule taken 24 hours after test meal intake

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2019
  2. Study start11 Oct 2019
  3. Primary completion30 Jun 2021
  4. Study completion30 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Twenty four male individuals from or living in the region of Luxembourg will be recruited for this study. The number of participants is based on a randomized block design, constituting of 6 blocks of 4 subjects, each will be served different sequences of test meals (A, B, C/A, C, B/B, C, A/B, A, C/C, A, B/C, B, A) in order to cancel out any potential effect of sequence of meals. Thus, each subject will act has his/her own control. Test meal intake will be separated by 1 week.
Masking
Single blind
Who is masked
Participant
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04078646
Sponsor's protocol ID
201710/04
Acronym
CAROPROT
Status last verified
Sep 2021
First submitted
8 Aug 2019
Last updated
23 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data of subjects will not be available for outside researchers.

Publications

  • Iddir M, Degerli C, Dingeo G, Desmarchelier C, Schleeh T, Borel P, Larondelle Y, Bohn T. Whey protein isolate modulates beta-carotene bioaccessibility depending on gastro-intestinal digestion conditions. Food Chem. 2019 Sep 1;291:157-166. doi: 10.1016/j.foodchem.2019.04.003. Epub 2019 Apr 1.

    PubMed 31006454
  • Soukoulis C, Bohn T. A comprehensive overview on the micro- and nano-technological encapsulation advances for enhancing the chemical stability and bioavailability of carotenoids. Crit Rev Food Sci Nutr. 2018 Jan 2;58(1):1-36. doi: 10.1080/10408398.2014.971353. Epub 2017 Jul 5.

    PubMed 26065668
  • Corte-Real J, Guignard C, Gantenbein M, Weber B, Burgard K, Hoffmann L, Richling E, Bohn T. No influence of supplemental dietary calcium intake on the bioavailability of spinach carotenoids in humans. Br J Nutr. 2017 Jun;117(11):1560-1569. doi: 10.1017/S0007114517001532. Epub 2017 Jun 27.

    PubMed 28651681

Questions about this trial

What is this clinical trial studying?

A study testing Intervention with soy protein isolate, Intervention with whey protein and Intervention without protein addition in people with Absorption; Chemicals and Healthy Diet, run by Luxembourg Institute of Health at 1 site in Luxembourg.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Luxembourg. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concentration of carotenoids in plasma triacyl-rich-lipoprotein (TRL) fraction (time frame: 10 hours postprandial, measured on 3 test clinical test days after test meal intake, interspersed by 1 week each). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04078646, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2021; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in